Similar Search Results

Pammolli, Fabio; Riccaboni, Massimo - Volkswirtschaftliche Fakultät, … - 2004

measures that are affecting demand for pharmaceuticals in all major markets. This Perspective considers the impact of the …

Persistent link: https://www.econbiz.de/10005109573

Economic Policy in Health Care: Sickness Absence and Pharmaceutical Cost

Granlund, David - Institutionen för Nationalekonomi, Umeå Universitet - 2007

generic pharmaceuticals during the first four years after the reform. The results also show that the price adjustment was not …

Persistent link: https://www.econbiz.de/10005197987

Medical Technology : Electromedicine Driving Healthcare

Heng, Stefan - 2015

Innovative products form the foundation for the international success of electromedical technology in Germany. This is shown both in the strong sales achieved by the German medical technology segment compared with other industrial countries and the export share of more than 70%, which even...

Persistent link: https://www.econbiz.de/10013015990

Barszczewska, Olga; Chami, Ralph; Piechota, Anna - In: Comparative economic research : Central and Eastern Europe 23 (2020) 2, pp. 103-115

The EU approved the first biosimilar drug in 2006. By 2017, the EU had authorized the highest number of biosimilars worldwide, acquiring considerable experience in their use and safety. In May 2019, the European Medicines Agency (EMA) search engine showed 54 authorized biosimilars. Biosimilars...

Persistent link: https://www.econbiz.de/10012417671

Trade in Medicines

Abbott, Frederick M. - 2016

, distribution and trade in pharmaceuticals and related supplies are subject to government regulatory control at a number of levels … differential regulation may unnecessarily hinder the cross-border movement of pharmaceuticals, particularly among regions that … include chapters covering intellectual property rights and regulatory data with respect to pharmaceuticals, as well as …

Persistent link: https://www.econbiz.de/10014133283

Risk or Benefit? Expenditures with Medicines Demanded by Judicial Decisions against Brazilian National Public Health System (SUS) and the Risk of Damage to Patients by Medicines In...

Faleiros, Daniel; Guerra, Augusto A.; Silva, Grazielle D.; … - 2008

Rationale: The policy of free and universal access to healthcare in Brazil, that assures the principle of equity based on the Federal Constitution of 1988, has caused repercussions as citizens become more aware of their rights. This has been achieved via lawsuits based on the statement: health...

Persistent link: https://www.econbiz.de/10014049881

An Ounce of Prevention or a Pound of Cure? Short- and Long-Run Effects of Pharmaceutical Patents on U.S. Health Care Expenditures

Johnson, Hilary S.; Johnson, Daniel K. N. - 2014

driving the costs of pharmaceuticals, and develop a structured vector autoregressive (SVAR) model to measure the social rate …-run prices in pharmaceuticals themselves, but with lower long-run prices in the aggregate medical sector which includes … pharmaceuticals as a component part. Further, the TRIPS Agreement and Hatch-Waxman Act to enable generic competition have both been …

Persistent link: https://www.econbiz.de/10014209235

The possibilities of day surgery system development within the health policy in Slovakia

Soltes, Vincent; Gavurová, Beáta - In: Health economics review 4 (2014) 35, pp. 1-12

Background: In the day surgery system are intertwined elements of state health policy, health care payers' interests, employers of health care system, as well as the interests and wishes of patients. A problem in the health policy is to find a way to regulate ambulatory and short-term surgical...

Persistent link: https://www.econbiz.de/10010526630

Lessons for Health Care Policy in the United States : Comparing Health Care Systems

Aspalter, Christian - 2012

This paper compares health care systems. It looks beyond normal academic, political, or journalistic rhetoric, by exactly sticking to facts, i.e. empirical data (in particular data provided by the WHO) and comprehensive case study analyses. The paper finds that a number of myths and common...

Persistent link: https://www.econbiz.de/10013113512

COVID-19 and the efficiency of health systems in Europe

Lupu, Dan; Țigănașu, Ramona - In: Health economics review 12 (2022) 1, pp. 1-15

Background: This study aims at analyzing the efficiency of the health systems of 31 European countries in treating COVID-19, for the period January 1, 2020 - January 1, 2021, by incorporating some factors from a multidimensional perspective. Methods: The methodology used in the research was Data...

Persistent link: https://www.econbiz.de/10013092939